US 12,240,913 B2
Anti-HER2/anti-4-1BB bispecific antibody and use thereof
Hyejin Chung, Seongnam-si (KR); Yeryoung Yong, Seongnam-si (KR); Kyeongsu Park, Seongnam-si (KR); Eunyoung Park, Seongnam-si (KR); Ui-Jung Jung, Seongnam-si (KR); Yangsoon Lee, Seongnam-si (KR); Eunjung Kim, Seongnam-si (KR); Yong-Gyu Son, Seongnam-si (KR); Wonjun Son, Seongnam-si (KR); Seawon Ahn, Seongnam-si (KR); Donghoon Yeom, Seongnam-si (KR); Chanmoo Lee, Seongnam-si (KR); Junghyeon Hong, Gwacheon-si (KR); Moo Young Song, Seongnam-si (KR); Eun-Jung Lee, Yongin-si (KR); Na Rae Lee, Seoul (KR); Young Bong Park, Yongin-si (KR); Eun-Jung Lee, Yongin-si (KR); and Taewang Kim, Yongin-si (KR)
Assigned to ABL BIO INC., Seongnam-si (KR); and YUHAN CORPORATION, Seoul (KR)
Filed by ABL Bio Inc., Seongnam-si (KR); and YUHAN CORPORATION, Seoul (KR)
Filed on Jul. 27, 2020, as Appl. No. 16/939,536.
Claims priority of provisional application 63/024,608, filed on May 14, 2020.
Claims priority of provisional application 62/878,951, filed on Jul. 26, 2019.
Prior Publication US 2021/0024650 A1, Jan. 28, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/00 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/32 (2013.01) [A61P 35/00 (2018.01); C07K 16/2878 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01)] 6 Claims
 
1. An anti-4-1 BB/anti-HER2 bispecific antibody comprising:
(a) an anti-4-1 BB antibody or an antigen-binding fragment thereof, wherein the anti-4-1 BB antibody or the antigen-binding fragment thereof is an anti-4-1 BB scFv of the anti-4-1 BB antibody, and
(b) an anti-HER2 antibody or an antigen-binding fragment thereof, wherein the anti-HER2 antibody or an antigen-binding fragment thereof is a full-length form of the anti-HER2 antibody, and the anti-4-1 BB scFv is linked at its N-terminus to the C-terminus of a heavy chain of the anti-HER2 antibody,
wherein the anti-4-1 BB antibody or the antigen-binding fragment thereof comprises:
(1) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 18 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 30, or
a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 24 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 33;
(2) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 19 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 30 or 31, or
a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 25 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 33 or 34;
(3) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 20 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 30 or 31; or
(4) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 21 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 30,
a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 22 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 31,
a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 27 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 33, or
a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 28 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 34, and
wherein the anti-HER2 antibody or an antigen-binding fragment thereof comprises:
a heavy chain comprising the amino acid sequence of SEQ ID NO: 73; and
a light chain comprising the amino acid sequence of SEQ ID NO: 75.